Advaxis Announces Phase 2 Study Results of Promising Vaccine Against HPV-Associated Cervical Cancer
News
Advaxis, Inc. recently announced in a press release that results from the first stage of its ongoing Phase II clinical trial (GOG-0265) investigating the company’s axalimogene filolisbac (ADXS-HPV) technology in the treatment of patients ... Read more